Paroxetine Hydrochloride Tablets 10mg (10tabs/blister, 3blisters/box)

• Dossier: Ctd
• Transport Package: Free
• Specification: 10mg
• Trademark: Sinolead
• Origin: China
• Model NO.: tablets

Product Description

 

 

Basic Info.

 

Generic Name	Paroxetine Hydrochloride Tablets 10mg
Strength	10mg
Packing	10tabs/blister,3blisters/box
Origin	China

Component:
Paroxetine Hydrochloride.

Character:

This product is a white oval, double-sided raised film coated sheet.

Indications:

Indications are for the treatment of various types of depression, including depression with anxiety and reactive depression. Common depressive symptoms: fatigue, sleep disturbances, lack of interest and pleasure in daily activities, loss of appetite. To treat obsessive-compulsive neurosis. Common obsessive-compulsive symptoms: Feeling repeated and persistent thoughts, impulses, or imaginings that can cause significant anxiety, leading to repetitive behaviors or mental activities. Treatment of panic disorder with or without agoraphobia. Common panic attack symptoms: palpitations, sweating, shortness of breath, chest pain, nausea, tingling, and near-death. Treatment of social phobia/social anxiety disorder. Common symptoms of social anxiety: palpitations, sweating, shortness of breath, etc. Often manifested as secondary to a significant or persistent fear of one or more social situations or performance situations, leading to avoidance. After satisfactory treatment, continued use of this product can prevent the recurrence of depression, panic disorder and obsessive-compulsive disorder.
 

Usage and dosage:

Oral, it is recommended to take it with breakfast every day, swallow the tablet completely, do not chew.

Adult:

Depression:

The usual dose is 20mg daily. After 2 to 3 weeks according to the patient's response, some patients need to increase the amount, with a weekly increase of 10mg, according to foreign experience up to 50mg per day, should follow the doctor's advice.

Obsessive compulsive neurosis:

The general dose is 40mg daily, and the initial dose is 20mg daily, in 10mg increments weekly. According to foreign experience, the maximum daily dose can reach 60mg.

Panic disorder:

The general dose is 40mg per day, the initial dose is 10mg per day, and depending on the patient's response, the daily dose is increased by 10mg per week, and the maximum daily dose can reach 50mg. It is generally believed that the symptoms of panic disorder may be aggravated in the early stage of treatment, so the initial dose is 10mg.

Social phobia/social anxiety Disorder:

The general dose is 20mg per day, if the patient does not respond to 20mg can be increased by 10mg per week according to the patient's clinical response, and the maximum daily dose can reach 50mg according to foreign experience. There is an interval of at least a week between dose changes.

As with all antidepressants, the dosage should be adjusted according to the condition during treatment. Patients should be treated long enough to consolidate the effect, and should be maintained for at least a few months after the recovery of depression, and longer for obsessive-compulsive neurosis and panic disorder. The withdrawal method is similar to other psychiatric drugs, which should be gradually reduced and should not be stopped suddenly.

Discontinuation of paxil

As with other psychotropic drugs, it is generally not advisable to stop abruptly (see the "Precautions" and "Adverse Reactions" sections). The tapering regimen used in recent clinical trials is to taper at weekly intervals, reducing the daily dose of 10mg per week from the previous week, and reducing the dose once a week.

When the daily dose was reduced to 20mg per day, the patient continued the dose for 1 week and then stopped. If symptoms of intolerance occur after reduction or withdrawal, a return to the previous dose can be considered. The doctor can then continue with the tapering regimen, but at a more gradual pace.

Kidney/Liver function impairment:

Since the blood concentration of this product is higher in patients with severe renal impairment (creatinine clearance [30ml/ min]) or severe liver damage than in healthy people, the recommended dose is 20mg daily, and if it is necessary to increase the dose, it should be limited to the lower limit of the dosage range.

Matters needing attention:

warn

Clinical deterioration and risk of suicide:

Adults or children with major depressive disorder (MDD) regardless of whether they are taking antidepressants. Are likely to experience worsening depressive symptoms and/or suicidal ideation and behavior (suicidal tendencies). This risk persists throughout the illness. Until the disease is in significant remission. Suicide is a known risk for depression and certain other mental illnesses, which are themselves the strongest predictors of suicide. It has long been thought that early treatment with antidepressants can induce deterioration and suicidal tendencies in some patients. Short-term antidepressants (SSRls class and others). A comprehensive analysis of placebo-controlled clinical trial data shows that in children. In adolescents and young adults (18-24 years), these drugs increase suicidal ideation and suicidal behavior (suicidality) in patients with major depression and other psychiatric disorders. Short-term clinical trials of antidepressants. Compared to placebo. There was no increase in suicide risk in adults over 24 years of age, but there was a decrease in suicide risk in adults over 65 years of age.

In children and adolescents with major depressive disorder, obsessive-compulsive disorder, or other psychiatric disorders. Comprehensive analysis of placebo-controlled clinical trials. That includes nine antidepressants. 24 short-term clinical trials in 4400 patients. In adults with major depression or other psychiatric disorders, a meta-analysis of placebo-controlled clinical trials included 11 antidepressants. 295 short-term clinical trials (median duration 2 months) in more than 77,000 patients. The risk of suicide varied between drugs, but almost all of the drugs tested showed an increased risk of suicide in younger patients; The absolute risk of suicide varies among different indications, with the highest incidence of major depressive disorder. Differences in risk (between drug and placebo) were relatively stable across age stratification and across indications, and these differences are shown in Table 1 (drug-placebo difference in number of suicides per 1,000 treated patients).